Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311


Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

Bhargava R, Dabbs DJ, Beriwal S, Yildiz IA, Badve P, Soran A, Johnson RR, Brufsky AM, Lembersky BC, McGuire KP, Ahrendt GM.

Mod Pathol. 2011 Mar;24(3):367-74. doi: 10.1038/modpathol.2010.209. Epub 2010 Nov 19.


Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.

Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.

Cancer. 2010 Mar 15;116(6):1431-9. doi: 10.1002/cncr.24876. Erratum in: Cancer. 2011 May 15;117(10):2238.


Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.


Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.


Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.

Precht LM, Lowe KA, Atwood M, Beatty JD.

Breast J. 2010 Jul-Aug;16(4):362-8. doi: 10.1111/j.1524-4741.2010.00935.x. Epub 2010 Apr 28.


The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.


Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.

Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y.

Ann Oncol. 2016 Mar;27(3):480-7. doi: 10.1093/annonc/mdv611. Epub 2015 Dec 23.


Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.

Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16.


Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.

Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y.

Breast Cancer. 2014 Sep;21(5):563-70. doi: 10.1007/s12282-012-0424-4. Epub 2012 Oct 30.


Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.

Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA.

Breast Cancer Res. 2012 May 23;14(3):R83.


Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.

Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, Sagan C, Antoine M, Penault-Llorca F, Vasseur B, Fumoleau P, Coudert BP.

Clin Cancer Res. 2007 Nov 1;13(21):6404-9.


Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L.

Eur J Surg Oncol. 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003. Epub 2011 Aug 16.


Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.

Horiguchi J, Oyama T, Takata D, Rokutanda N, Nagaoka R, Odawara H, Tokiniwa H, Tozuka K, Kikuchi M, Sato A, Takeyoshi I.

Anticancer Res. 2011 Sep;31(9):3041-6.


Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.


Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.

Breast Cancer Res Treat. 2010 Jan;119(1):119-26. doi: 10.1007/s10549-009-0499-6. Epub 2009 Aug 8.


Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA.

Ann Surg Oncol. 2011 Oct;18(10):2851-7. doi: 10.1245/s10434-011-1665-8. Epub 2011 Mar 26.


Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.

Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA.

J Clin Oncol. 2009 Oct 1;27(28):4693-700. doi: 10.1200/JCO.2008.21.4163. Epub 2009 Aug 31.


Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

Constantinidou A, Smith I.

Breast. 2011 Oct;20 Suppl 3:S158-61. doi: 10.1016/S0960-9776(11)70316-2. Review.


Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.


Supplemental Content

Support Center